AstraZeneca’s experimental blood cancer drug gets US priority review
British-Swedish AstraZeneca’s drug for treatment of a form of blood cancer has been granted a Priority Review in the US by the drug.
Drugs
Health
Pharma
Drugs
Health
Pharma
Gilead signs six global pacts to make, sell generic HIV preventive drug
Gilead Sciences, Inc. has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical makers to make and sell its generic lenacapavir drug for the prevention.
Drugs
Health
Pharma
AstraZeneca, Daiichi’s Enhertu drug gets FDA’s priority review in US
AstraZeneca and Daiichi Sankyo got a priority review from the Food and Drug Administration for their Enhertu drug to treat a form of.
Drugs
Health
Pharma
FDA approves Cobenfy, a new treatment for schizophrenia
HQ Team 27 September, 2024: The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) for the treatment of schizophrenia in.
Drugs
Health
Pharma
FDA warning on Veozah: Liver injury risk linked to menopausal drug
HQ Team September 13, 2024: The U.S. Food and Drug Administration (FDA) has issued a safety warning about Veozah (fezolinetant), a medication prescribed.
Drugs
Health
Pharma
US smokers need photo ID to prove new age limit set by the FDA
The US drug regulator raised the age limit of people who want to buy tobacco products by three years to 30, and retailers.
Drugs
Health
Pharma
Regulator okays Insulet’s insulin pump in US to treat type 2 diabetes
Insulet Corporation, a tubeless insulin pump maker, got clearance from the US Food and Drug Administration to add diabetes type 2 adult patients.
Drugs
Health
Pharma
US drug regulator blocks Regeneron’s blood cancer therapy
The US regulatory body has rejected Regeneron Pharmaceuticals, Inc.,’s blood cancer drug as it did not meet the pre-approval standards of the agency.
Drugs
Health
Pharma
US-based ARS’s nasal spray to treat allergic reactions gets FDA nod
ARS Pharmaceuticals, a US-based biopharmaceutical company, got the nation’s drug regulator’s approval for a nasal spray to treat allergic reactions in adult and.
Drugs
Health
Pharma
US regulator rejects Lykos’s MDMA therapy, wants more data
Lykos Therapeutics’s ecstasy drug or midomafetamine capsules for the treatment of post-traumatic stress disorder in adults was rejected by the US drug regulatory.